Stryker Corporation (NYSE:SYK) Receives $421.11 Average PT from Brokerages

Stryker Corporation (NYSE:SYK) has earned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $421.1053.

SYK has been the topic of a number of recent research reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Barclays reissued an “overweight” rating and set a $469.00 price target on shares of Stryker in a research report on Monday, February 2nd. Evercore set a $390.00 price objective on Stryker in a research report on Monday, January 5th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a research report on Tuesday, January 27th.

Stryker Stock Performance

Shares of Stryker stock opened at $338.15 on Friday. The stock’s fifty day moving average is $352.61 and its two-hundred day moving average is $359.31. The company has a market capitalization of $129.50 billion, a PE ratio of 40.26, a price-to-earnings-growth ratio of 2.01 and a beta of 0.92. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. Stryker has a 52 week low of $319.32 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The company had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the company posted $4.01 EPS. Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, analysts expect that Stryker will post 14.92 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Stryker by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares in the last quarter. State Street Corp boosted its position in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC boosted its position in Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after acquiring an additional 741,542 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.